FY2026 Earnings Estimate for InflaRx Issued By HC Wainwright

Key Points

• HC Wainwright raised its FY2026 loss-per-share estimate to $0.22 from $0.35, compared with the current analyst consensus loss estimate of $0.31 per share. It also forecast losses of $0.25 per share in FY2027 and $0.27 in FY2028.
• InflaRx reported a third-quarter loss of $0.02 per share, beating the consensus estimate of a $0.06 loss by $0.04. The company said its €153.3 million in cash and marketable securities should fund operations and clinical development through 2029.
• The company plans Phase 2 trials of izicopan for ANCA-associated vasculitis in 2027, with initial results expected in 2028. Its projected $1.5 billion–$2 billion peak sales opportunity depends on successful trials and commercialization.

InflaRx N.V. (NASDAQ:IFRX - Free Report) - Stock analysts at HC Wainwright raised their FY2026 EPS estimates for shares of InflaRx in a report released on Tuesday, November 3rd. HC Wainwright analyst M. Keller now anticipates that the company will earn ($0.22) per share for the year, up from their prior forecast of ($0.35). The consensus estimate for InflaRx's current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for InflaRx's Q4 2026 earnings at ($0.04) EPS, FY2027 earnings at ($0.25) EPS and FY2028 earnings at ($0.27) EPS.

IFRX has been the subject of several other reports. Zacks Research downgraded InflaRx from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of InflaRx in a research note on Monday, September 21st. Cantor Fitzgerald boosted their target price on InflaRx from $4.00 to $6.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, Needham & Company LLC initiated coverage on InflaRx in a research note on Monday, September 14th. They set a "buy" rating and a $8.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.43.

InflaRx Price Performance

NASDAQ IFRX opened at $1.48 on Thursday. InflaRx has a 52-week low of $0.80 and a 52-week high of $2.95. The business's 50-day moving average price is $1.83 and its 200 day moving average price is $1.63.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.04.

Institutional Trading of InflaRx

A number of institutional investors have recently modified their holdings of IFRX. China Universal Asset Management Co. Ltd. increased its holdings in InflaRx by 47.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 23,600 shares of the company's stock valued at $44,000 after buying an additional 7,600 shares in the last quarter. T3 Companies LLC lifted its position in shares of InflaRx by 32.9% during the 3rd quarter. T3 Companies LLC now owns 440,000 shares of the company's stock valued at $792,000 after acquiring an additional 108,986 shares during the period. SteelPeak Wealth LLC acquired a new stake in shares of InflaRx during the 3rd quarter valued at approximately $419,000. AXQ Capital LP purchased a new stake in shares of InflaRx during the 2nd quarter worth approximately $41,000. Finally, Montanova Capital LLC boosted its stake in shares of InflaRx by 189.1% during the 2nd quarter. Montanova Capital LLC now owns 22,933,910 shares of the company's stock worth $51,372,000 after acquiring an additional 15,000,000 shares in the last quarter. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

More InflaRx News

Here are the key news stories impacting InflaRx this week:

• Positive Sentiment: InflaRx plans two Phase 2 AAV trials in 2027, including a study in patients with kidney involvement and an open-label study testing whether izicopan can replace corticosteroids. The company expects initial results in 2028. InflaRx Capital Markets Day announcement
• Positive Sentiment: The company estimates izicopan could reach peak AAV sales of $1.5 billion to $2 billion, while acknowledging that this is a forecast rather than established commercial performance. It also plans studies in aHUS and IgA nephropathy. RTTNews report on izicopan plans
• Positive Sentiment: InflaRx reported €153.3 million in cash, cash equivalents and marketable securities at September 30, which it expects to fund operations and clinical development through 2029. Third-quarter EPS was a loss of $0.02, narrower than analysts’ expected $0.04 loss. Third-quarter earnings report
• Neutral Sentiment: The company also announced an advisory board of experts in vasculitis, nephrology and immune-mediated kidney disease, adding specialist input as it develops the program. Izicopan program and advisory board announcement
• Negative Sentiment: The main AAV trial data are not expected until 2028, and the sales opportunity depends on successful future studies and commercialization. That leaves substantial development and execution risk before the projections can be validated.

About InflaRx

InflaRx N.V. NASDAQ: IFRX is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Founded in 2007 and headquartered in Jena, Germany, the company's research is centered on the complement system, an important part of the immune response. InflaRx seeks to selectively block complement component C5a, a potent inflammatory mediator, while preserving other aspects of immune-system function.

The company's lead product, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.